Arabic Arabic English English French French German German
dark

XRad Therapeutics Announces First Patient Dosed in Phase 1a Clinical Trial of XRD-0394 for Metastatic, Locally-Advanced or Recurrent Solid Tumors

XRad Therapeutics today announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy (RT) for the treatment of metastatic, locally-advanced or recurrent solid tumors. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Engagement, Interoperability, and the Future of the Healthcare Tech Stack

Next Post

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease

Related Posts
Total
0
Share